ILT2/CD85j/LILRB1 Antibody (292319) [Alexa Fluor® 405]

• Reactivity: Hu
• Applications: WB, B/N, CyTOF-ready
• Clone: 292319
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 405

ILT2/CD85j/LILRB1 Antibody (292319) [Alexa Fluor® 405] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human LILRB1/CD85j/ILT2
  Gly24-His458
  Accession # Q8NHL6
• Specificity: Detects human LILRB1/CD85j/ILT2 in direct ELISAs and Western blots. In direct ELISAs, no cross-reactivity with recombinant human (rh) ILT1, 3, 4, 5, rhLIR-6 or rhLIR-8 is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-reported
  • Neutralization
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for ILT2/CD85j/LILRB1 Antibody (292319) [Alexa Fluor® 405]

• CD85 antigen-like family member J
• CD85j antigen
• CD85j
• Ig-like transcript 2
• ILT2
• ILT-2
• ILT2FLJ37515
• Immunoglobulin-like transcript 2
• leukocyte Ig-like receptor-1
• Leukocyte immunoglobulin-like receptor 1
• leukocyte immunoglobulin-like receptor subfamily B member 1 soluble isoform
• leukocyte immunoglobulin-like receptor subfamily B member 1
• leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains)
• LILRB1
• LIR1
• LIR1LIR-1MIR-7CD85MIR7CD85 antigen
• member 1
• MIR7
• Monocyte/macrophage immunoglobulin-like receptor 7

Background

The immunoglobulin-like transcript (ILT) family of activating and inhibitory type immunoreceptors are expressed on many leukocyte subsets and function in the regulation of immune responses (1‑3). This family was also named leukocyte Ig-like receptors (LIR) and monocyte/macrophage Ig-like receptors (MIR). ILTs share significant homology with killer cell Ig-like receptors (KIR). The ILT genes are located on human chromosome 19q13.4 in the leukocyte receptor complex, which also include the genes encoding KIRs (4). With the exception of ILT-6, which is a soluble molecule, all ILT family members are type I transmembrane proteins having two or four extracellular Ig-like domains (2, 3). One subset of the ILT receptors (referred to as subfamily B of the LIRs) has long cytoplasmic tails containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) that inhibit signaling events by recruiting SH2-containing protein tyrosine phosphatase-1. Another subset of the ILT receptors (referred to as subfamily A of the LIRs) contains activating receptors with short cytoplasmic regions that lack signal transduction motifs. These receptors contain a basic arginine residue within their transmembrane domains, which allows association with Fc R gamma , an immunoreceptor tyrosine-based activation motif (ITAM)-bearing signal adapter protein (1‑3). ILT2, also known as LIR1, MIR7, and CD85j, is expressed on most monocytes, dendritic cells, and mature B cells (1‑3). It is also expressed on small percentages of T cells and NK cells. ILT2 has four extracellular Ig-like domains and three cytoplasmic ITIMs. It functions as an inhibitory receptor that prevents cellular activation. ILT2 has been shown to bind classical (HLA-A and -B) and nonclassical (HLA-G1, -E and -F) MHC class I molecules (MHCI) (1‑3). ILT2 also binds with high affinity to an MHC class I homologue from human cytomegalovirus (3). Ligation of ILT2 by MHC class I may function to poise cellular activation thresholds and inhibit various leukocyte effector mechanisms that are regulated by MHC class I molecules on target cells.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • Q8NHL6()